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ABSTRACT	76 
	77 
BACKGROUND:	 An	 inverse	 relationship	 between	 allergies	 with	 glioma	 risk	 has	 been	78 
reported	 in	 several	 but	 not	 all	 epidemiological	 observational	 studies.	 We	 performed	 an	79 
analysis	of	genetic	variants	associated	with	atopy	to	assess	the	relationship	with	glioma	risk	80 
using	 Mendelian	 randomization	 (MR),	 an	 approach	 unaffected	 by	 biases	 from	 temporal	81 
variability	and	reverse	causation	that	might	have	affected	earlier	investigations.	82 
	83 
METHODS:	Two-sample	MR	was	undertaken	using	genome-wide	association	study	data.	We	84 
used	single	nucleotide	polymorphisms	(SNPs)	associated	with	atopic	dermatitis,	asthma	and	85 
hay	fever,	 IgE	 levels	and	self-reported	allergy	as	 instrumental	variables.	We	calculated	MR	86 
estimates	for	the	odds	ratio	(OR)	for	each	risk	factor	with	glioma	using	SNP-glioma	estimates	87 
from	12,488	 cases	 and	18,169	 controls,	 using	 inverse-variance	weighted	 (IVW),	maximum	88 
likelihood	 estimation	 (MLE),	weighted	median	 estimate	 (WME)	 and	mode-based	 estimate	89 
(MBE)	 methods.	 Violation	 of	 MR	 assumptions	 due	 to	 directional	 pleiotropy	 were	 sought	90 
using	MR-Egger	regression	and	HEIDI-outlier	analysis.		91 
	92 
RESULTS:	Under	IVW,	MLE,	WME	and	MBE	methods,	associations	between	glioma	risk	with	93 
asthma	and	hay	fever,	self-reported	allergy	and	IgE	 levels	were	non-significant.	An	 inverse	94 
relationship	 between	 atopic	 dermatitis	 and	 glioma	 risk	was	 found	 by	 IVW	 (OR=0.96,	 95%	95 
confidence	interval	[CI]:	0.93-1.00,	P=0.041)	and	MLE	(OR=0.96,	95%	CI=0.94-0.99,	P=0.003)	96 
but	not	by	WME	(OR=0.96,	95%	CI:	0.91-1.01,	P=0.114)	or	MBE	(OR=0.97,	95%	CI:	0.92-1.02,	97 
P=0.194).		98 
	99 
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CONCLUSIONS:	 Our	 investigation	 does	 not	 provide	 strong	 evidence	 for	 relationship	100 
between	atopy	and	the	risk	of	developing	glioma,	but	findings	do	not	preclude	a	small	effect	101 
in	relation	to	atopic	dematitis.	Our	analysis	also	serves	to	illustrate	the	value	of	using	several	102 
MR	methods	to	derive	robust	conclusions.		103 
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BACKGROUND	125 
	126 
Although	glioma	accounts	for	around	80%	of	malignant	primary	brain	tumours	[1],	to	date	127 
few	 aetiological	 risk	 factors	 are	 well	 established	 for	 the	 disease	 [2].	 Over	 the	 past	 three	128 
decades	the	search	for	an	immune-mediated	risk	factor	that	might	influence	risk	has	led	to	129 
studies	 of	 a	 possible	 relationship	 between	 multiple	 allergic	 conditions	 and	 autoimmune	130 
disorders	with	glioma	[3].	131 
	132 
Several	case-control	studies	have	shown	that	self-reported	allergic	conditions	may	protect	133 
against	 glioma	 [4].	 For	 example,	 in	 the	 International	Adult	 Brain	 Tumour	 Study,	 based	on	134 
1,178	glioma	patients,	an	odds	ratio	(OR)	of	0.59	was	found	for	any	self-reported	allergy	[5].	135 
Other	case-control	studies	have	reported	similar	ORs,	however	most	have	been	reliant	on	136 
substantial	 numbers	 of	 proxy	 informants	 (up	 to	 44%)	 [4,	 6],	 and	 potential	 bias	 as	 a	137 
consequence	 of	 how	 controls	 were	 ascertained,	 thereby	 casting	 doubt	 on	 findings.	 In	138 
contrast	 to	 case-control	 studies,	 evidence	 for	 an	 association	 between	 glioma	 and	 allergy	139 
from	cohort-based	analyses	has	been	less	forthcoming	[7],	although	such	studies	have	been	140 
poorly	powered	to	demonstrate	a	relationship.	141 
	142 
Assaying	 IgE	 potentially	 reduces	 bias	 stemming	 from	 self-reporting	 despite	 levels	 not	143 
necessarily	 corresponding	 to	 specific	 allergies	 or	 equating	 to	 a	 single	 allergic	 response.	144 
Nevertheless	measurement	of	IgE	has	been	explored	by	a	number	of	researchers	seeking	to	145 
identify	risk	factors	for	glioma	[8-10].	In	a	case-control	study	of	228	cases	and	289	controls	146 
performed	in	2004,	self-reported	allergies	and	IgE	levels	were	both	inversely	associated	with	147 
glioma,	but	concordance	between	the	two	outcomes	was	poor	[8].	In	a	larger	study	of	535	148 
cases	and	532	controls,	both	self-reported	allergies	and	IgE	levels	were	inversely	related	to	149 
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glioma	risk,	however	IgE	levels	in	patients	were	affected	by	temozolomide	treatment	[11].	A	150 
case-control	 study	 nested	within	 the	 European	 Prospective	 Investigation	 into	 Cancer	 and	151 
Nutrition	 cohort	 based	 on	 prospectively	 collected	 serum	 IgE	 levels	 reported	 a	 non-152 
significant	OR	of	0.73	[9].	A	similar	nested	case-control	study	performed	in	the	USA	based	153 
on	181	cases	reported	non-significant	OR	of	0.72	for	high	serum	IgE	[10].	154 
	155 
Several	mechanisms	have	been	proposed	to	explain	a	possible	association	between	atopic	156 
disease	 and	 glioma	 [12].	 The	 findings	 could	 reflect	 a	 true	 causal	 effect	 of	 the	heightened	157 
immune	 function	 reported	 for	 atopy	 on	 tumour	 development.	 Alternatively,	 the	158 
associations	 observed	 might	 be	 non-causal,	 arising	 as	 a	 consequence	 of	 methodological	159 
biases	 inherent	 in	the	study	design.	 Imprecisely	defined	exposures	such	as	allergic	disease	160 
are	 likely	 to	 have	 affected	 the	 validity	 of	 the	 findings	 of	 both	 case-control	 and	 cohort	161 
studies.	The	heterogeneous	description	of	allergy	in	studies	and	different	levels	of	detail	in	162 
self-reporting	 on	 individual	 allergies	 complicate	 interpretation	 of	 the	 results.	 Additional	163 
biases	 include	 possible	 selection	 bias	 in	 controls,	 recall	 bias	 from	 self-reported	 allergy	164 
assessment	 and	 reverse	 causation	 or	 confounding	 from	 unmeasured	 effects.	 Finally,	 the	165 
high	 frequency	 of	 exposure	 ascertainment	 by	 proxy	 for	 cases	 is	 also	 likely	 to	 have	166 
systematically	biased	findings.		167 
	168 
Mendelian	 randomization	 (MR)	 analysis	 can	 be	 used	 to	 minimise	 potential	 biases	 in	169 
conventional	observational	studies	and	to	determine	the	causal	association	of	an	exposure	170 
with	an	outcome,	such	as	disease	risk	[13].	The	causal	association	can	also	be	manifested	by	171 
common	 genetic	 and	 biological	 pathways	 that	 determine	 two	 sequentially	 developed	172 
phenotypes,	such	as	an	atopic	trait	and	glioma	risk.	Atopy	has	a	strong	heritable	basis	[14,	173 
15],	 and	 thus	 far	 genome-wide	 association	 studies	 (GWAS)	 have	 identified	 over	 50	 loci	174 
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associated	with	different	atopy-related	traits	[16].	The	alleles	associated	with	atopy	should	175 
be	randomly	assigned	to	offspring	from	parents	during	mitosis,	a	process	analogous	to	the	176 
random	assignment	of	subjects	to	an	exposure	of	interest	in	randomised	clinical	trials.	Thus,	177 
genetic	 scores	 summarising	 the	 effects	 of	 single	 nucleotide	 polymorphisms	 (SNPs)	178 
associated	 with	 atopy-related	 traits	 can	 serve	 as	 instrumental	 variables	 (IVs)	 in	 a	 MR	179 
analysis	of	atopy	and	glioma	risk.	180 
	181 
To	examine	the	nature	of	the	association	between	atopy	and	glioma,	we	implemented	two-182 
sample	MR	 [17]	 to	 estimate	 associations	 between	 atopy-associated	 SNPs	 and	 glioma	 risk	183 
using	 summary	 data	 from	 the	 recent	 GWAS	 meta-analysis	 performed	 by	 the	 Glioma	184 
International	Case-Control	Consortium	study	(GICC)	[18].		185 
	186 
	187 
	188 
	189 
	190 
	191 
	192 
	193 
	194 
	195 
	196 
	197 
	198 
	199 
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METHODS	200 
	201 
Two-sample	MR	was	undertaken	using	GWAS	data.	Ethical	approval	was	not	sought	for	this	202 
specific	project	because	all	data	came	from	the	summary	statistics	of	published	GWAS,	and	203 
no	individual-level	data	were	used.		204 
	205 
Glioma	genotyping	data	206 
Glioma	 genotyping	 data	 were	 derived	 from	 the	 most	 recent	 meta-analysis	 of	 GWAS	 in	207 
glioma,	which	 related	 >10	million	 genetic	 variants	 (after	 imputation)	 to	 glioma,	 in	 12,488	208 
glioma	patients	and	18,169	controls	 from	eight	 independent	GWAS	datasets	of	 individuals	209 
of	 European	 descent	 [18]	 (Additional	 file	 2:	 Table	 S1).	 Comprehensive	 details	 of	 the	210 
genotyping	and	quality	control	of	the	seven	GWAS	have	been	previously	reported	[18].	211 
	212 
Genetic	variant	instruments	for	atopic	traits	213 
SNPs	 associated	 with	 each	 of	 the	 atopy-related	 traits	 investigated	 –	 atopic	 dermatitis	214 
(eczema),	asthma	and	hay	fever,	IgE	level,	and	self-reported	allergy	by	the	NHGRI-EBI	GWAS	215 
Catalog	[19-26]	at	genome-wide	significance	(i.e.	P≤5.0	×	10-8)	in	individuals	with	European	216 
ancestry	were	used	as	 IVs.	To	avoid	co-linearity	between	SNPs	for	each	trait,	we	excluded	217 
SNPs	that	were	correlated	(i.e.	r2	value	of	≥0.001)	within	each	trait,	and	only	considered	the	218 
SNPs	with	 the	strongest	effect	on	the	trait	 for	use	as	 IVs	 (Additional	 file	3:	Table	S2).	For	219 
each	 SNP,	we	 recovered	 the	 chromosome	position,	 risk	 allele,	 association	 estimates	 (per-220 
allele	 log-OR)	 and	 standard	 errors	 (SEs),	 summarised	 in	 Table	 1.	 The	 allele	 that	 was	221 
associated	with	increased	risk	of	the	exposure	was	considered	the	effect	allele.	For	IgE	level,	222 
the	allele	associated	with	an	 increase	 in	serum	 IgE	was	considered	the	effect	allele.	Allele	223 
frequencies	 for	 these	 SNPs	 were	 compared	 between	 the	 atopy-related	 trait	 and	 glioma	224 
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datasets	to	ensure	that	the	effect	estimates	were	recorded	with	respect	to	the	same	allele.	225 
Gliomas	are	heterogeneous	and	different	 tumour	subtypes,	defined	 in	part	by	malignancy	226 
grade	(for	example,	pilocytic	astrocytoma	World	Health	Organization	(WHO)	grade	I,	diffuse	227 
‘low-grade'	glioma	WHO	grade	II,	anaplastic	glioma	WHO	grade	III	and	glioblastoma	[GBM]	228 
WHO	grade	IV)	can	be	distinguished	[27].	For	the	sake	of	brevity	we	considered	gliomas	as	229 
being	either	GBM	or	non-GBM.		230 
	231 
Two-sample	Mendelian	randomization	method	232 
The	 association	 between	 each	 atopy-related	 trait	 and	 glioma	was	 examined	 using	MR	on	233 
summary	 statistics	 using	 the	 inverse	 variance	 weighted	 (IVW)	 method	 and	 maximum	234 
likelihood	estimation	(MLE)	as	per	Burgess	et	al.	[28].	The	IVW	ratio	estimate	(β)	of	all	SNPs	235 
associated	with	each	atopy-related	trait	on	glioma	risk	was	calculated	as	follows:	236 
	237 
β =  !!!!!!!!!! !!!!!!!!!    .	
	238 
Where	Xk	corresponds	to	the	association	of	SNP	k	(as	log	of	the	OR	per	risk	allele)	with	the	239 
atopy-related	trait	Y,	Yk	 is	 the	association	between	SNP	k	and	glioma	risk	 (as	 log	OR)	with	240 
standard	error	!!! .	 The	estimate	 for	 (β)	 represents	 the	 causal	 increase	 in	 the	 log	odds	of	241 
glioma	for	each	trait.	The	standard	error	of	the	combined	ratio	estimate	is	given	by:		242 
	243 
se(β) =  1!!!!!!!!!    .	
	244 
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For	 the	 maximum	 likelihood	 estimate,	 a	 bivariate	 normal	 distribution	 for	 the	 genetic	245 
associations	 was	 assumed,	 and	 the	 R	 function	 optim	 was	 used	 to	 estimate	!.	 se(β)	 was	246 
calculated	using	observed	information.	The	correlation	between	the	errors	of	!!	and	!!	was	247 
taken	to	be	0	as	they	were	derived	from	independent	studies.		248 
	249 
A	central	 tenet	 in	MR	 is	 the	absence	of	pleiotropy	 (i.e.	 a	 gene	 influencing	multiple	 traits)	250 
between	 the	SNPs	 influencing	 the	exposure	and	outcome	disease	 risk	 [13].	This	would	be	251 
revealed	as	deviation	from	a	linear	relationship	between	SNPs	and	their	effect	size	for	atopy	252 
and	glioma	risk.	To	examine	for	violation	of	the	standard	IV	assumptions	in	our	analysis	we	253 
first	performed	MR-Egger	regression,	as	well	as	HEIDI-outlier	analysis	as	per	Zhu,	Z	et	al.	[29]	254 
imposing	 the	 advocated	 threshold	 of	 P	 ≤0.01.	 Additionally	 we	 derived	 weighted	 median	255 
estimates	(WME)	[30]	and	mode-based	estimates	(MBE)	[31]	to	establish	the	robustness	of	256 
findings.	257 
	258 
Atopic	 dermatitis,	 asthma	 and	 hay	 fever,	 and	 self-reported	 allergyand	 all	 of	 the	 disease	259 
outcomes	 (all	 glioma,	 GBM	 and	 non-GBM	 glioma)	 are	 binary	 The	 causal	 effect	 estimates	260 
therefore	represent	the	odds	for	outcome	disease	risk	per	unit	increase	in	the	log	OR	of	the	261 
exposure	disease	[32].	These	ORs	have	been	converted	to	represent	the	OR	for	the	outcome	262 
disease	per	doubling	in	odds	of	the	exposure	disease	to	aid	interpretation	[32].		263 
	264 
For	 each	 statistical	 test	 we	 considered	 a	 global	 significance	 level	 of	 P <0.05	 as	 being	265 
satisfactory	to	derive	conclusions.	To	assess	the	robustness	of	our	conclusions,	we	 initially	266 
imposed	 a	 conservative	 Bonferroni-corrected	 significance	 threshold	 of	 0.0125	 (i.e.	 0.05/4	267 
atopy-related	traits).	We	considered	a	P	value	≥0.05	as	non-significant	(i.e.	no	association),	a	268 
P	value	<0.05	as	evidence	for	a	potential	causal	association,	and	a	P	<0.0125	as	significant	269 
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evidence	 for	 an	 association.	 All	 statistical	 analyses	 were	 undertaken	 using	 R	 software	270 
(Version	 3.1.2).	 The	 meta	 and	 gsmr	 packages	 were	 used	 to	 generate	 forest	 plots	 and	271 
perform	HEIDI-outlier	analysis	[29].	272 
	273 
The	power	of	a	MR	investigation	depends	greatly	on	the	proportion	of	variance	in	the	risk	274 
factor	that	is	explained	by	the	IV.	We	estimated	study	power	a	priori	using	the	methodology	275 
of	 Burgess	 et	 al.	 [33],	 making	 use	 of	 published	 estimates	 of	 the	 heritability	 of	 trait	276 
associated	IV	SNPs	[34-36],	as	well	as	estimates	found	by	direct	calculation	(Additional	file	277 
4:	Table	S3),	and	the	reported	effect	of	each	trait	on	glioma	risk	reported	in	meta-analysis	of	278 
epidemiological	studies	[18].	Additional	file	5:	Table	S4	shows	the	range	of	ORs,	for	which	279 
we	had	less	than	80%	power	to	detect	for	each	of	the	four	atopy-related	traits.	280 
	281 
Simulation	model	282 
Through	 simulation	we	evaluated	 the	 suitability	 of	 using	 each	employed	MR	method	 in	 a	283 
two-sample	 setting	with	 binary-exposure	 and	 binary-outcome	 data.	 For	 i	 index	N	 genetic	284 
variants	 and	 j	 index	 individuals	 genetic	 variants	 gij	 were	 generated	 independently	 by	285 
sampling	 from	 a	 Binomial(2,pj)	 distribution	 with	 probability	 pj	 drawn	 from	 a	286 
Uniform(0.1,0.9)	distribution,	to	mimic	bi-allelic	SNPs	in	Hardy-Weinberg	equilibrium.	Let	wj	287 
correspond	 to	 the	per-allele	OR	 for	 the	exposure	disease,	 sampled	 from	ORs	 reported	 for	288 
genome-wide	significant	SNPs	reported	in	the	GWAS	Catalog	[37],	and	v	be	the	OR	for	the	289 
outcome	 disease	 per	 doubling	 in	 odds	 of	 the	 exposure	 disease.	 For	 each	 individual,	290 
exposure	disease	odds	xj,	outcome	disease	odds	yj,	exposure	disease	status	aj,	and	outcome	291 
disease	status	bj	were	determined	as	follows:		292 
!! = !! !!!!"!!!! 	
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!! = !!×2log!!! × log!!	!!  ~ Binomial(1, !!1+  !!) 	!!  ~ Binomial(1, !!1+  !!) 	
Data	for	1,000,000	individuals	were	simulated	and	partitioned	at	random	to	reflect	the	two-293 
sample	setting.	Cases	and	controls	for	the	exposure	and	outcome	GWAS	were	sampled	from	294 
each	half	of	the	dataset	using	the	exposure	and	outcome	disease	statuses	of	each	individual,	295 
and	association	statistics	computed	under	an	additive	 logistic	regression	model.	To	ensure	296 
the	simulated	data	closely	resembled	the	atopy-related	trait	and	glioma	data,	the	simulation	297 
analysis	was	repeated	for	each	binary	atopy-related	trait	using	the	same	number	of	genetic	298 
variants	as	IVs	and	the	same	numbers	of	case	and	control	individuals	as	used	to	estimate	the	299 
atopy-related	trait	and	glioma	association	statistics	(Additional	file	6:	Table	S5).	Parameters	300 
x0=0.0005	and	y0=0.01	were	chosen	to	ensure	the	prevalence	of	the	simulated	exposure	and	301 
outcome	diseases	were	 similar	 to	 that	 of	 the	 atopy-related	 traits	 and	 glioma	 respectively	302 
(Additional	file	6:	Table	S5).	To	determine	the	suitability	of	each	MR	method	we	considered	303 
two	scenarios:	(i)	no	causal	relationship	between	exposure	and	outcome	(v=1.00)	and	(ii)	a	304 
causal	 relationship	 between	 exposure	 and	 outcome	 (v=1.33).	 We	 performed	 100	305 
simulations	for	each	scenario	for	each	binary	atopy-related	trait.		306 
	307 
	308 
	309 
	310 
	311 
	312 
	313 
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RESULTS	314 
	315 
The	atopic	dermatitis	 risk	 SNP	 rs909341,	which	 is	highly	 correlated	with	 the	 chromosome	316 
20q13.33	glioma	risk	SNP	rs2297440	(D’=0.89,	r2=0.77),	was	strongly	associated	with	risk	of	317 
glioma	(P=2.10x10-34).	Testing	for	pleiotropy	using	HEIDI	outlier-analysis	formally	 identified	318 
rs909341	 as	 violating	 the	 assumption	 of	 the	 instrument	 on	 the	 outcome.	 Henceforth	we	319 
confined	our	analysis	of	the	relationship	between	atopic	dermatitis	and	glioma	to	a	dataset	320 
excluding	this	SNP.		321 
	322 
Figure	1	shows	forest	plots	of	ORs	for	glioma	generated	from	the	SNPs.	There	was	minimal	323 
evidence	of	heterogeneity	between	variants	for	asthma	and	hay	fever,	atopic	dermatitis,	IgE	324 
levels	and	self-reported	allergy	(respective	 I2	and	Phet	values	being	28%	and	0.192,	8%	and	325 
0.377,	 0%	 and	 0.444,	 and	 0%	 and	 0.707).	 Including	 rs909341	 in	 the	 analysis	 for	 atopic	326 
dermatitis,	 the	 I2	 value	 was	 90%	 and	 Phet	 <	 10-4	 (Additional	 file	 1:	 Figure	 S1),	 providing	327 
further	evidence	that	inclusion	of	this	SNP	would	invalidate	the	MR	analysis.	328 
	329 
The	results	of	the	IVW,	MLE,	WME,	MBE	and	MR-Egger	methods	are	summarised	in	Table	2.	330 
Using	 the	 IVW	method	 to	 pool	 results	 from	 individual	 SNPs,	 no	 associations	 (i.e.	P≥0.05)	331 
were	identified	between	genetically	conferred	risk	of	raised	IgE	level	(OR=0.88,	95%	CI=0.69-332 
1.13,	 P=0.319),	 asthma	 and	 hay	 fever	 (OR=0.96,	 95%	 CI=0.90-1.03,	 P=0.248),	 or	 self-333 
reported	 allergy	 (OR=1.03,	 95%	 CI=0.95-1.11,	 P=0.534)	 with	 risk	 of	 all	 glioma.	 There	 was	334 
some	 support	 for	 an	 inverse	 relationship	 between	 atopic	 dermatitis	 and	 glioma	 risk	335 
(OR=0.96,	 95%	CI=0.93-1.00,	P=0.041),	 albeit	 not	 significant	 after	 adjustment	 for	multiple	336 
testing.	337 
	338 
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Using	MLE,	no	associations	were	 identified	between	asthma	and	hay	 fever	 (OR=0.96,	95%	339 
CI=0.93-1.00,	 P=0.066),	 IgE	 levels	 (OR=0.88,	 95%	 CI=0.74-1.05,	 P=0.157)	 or	 self-reported	340 
allergy	 (OR=1.02,	95%	CI=0.97-1.08,	P=0.429)	with	risk	of	all	glioma.	For	atopic	dermatitis,	341 
an	 OR	 of	 0.96	 (95%	 CI=0.94-0.99,	 P=0.003)	 was	 shown,	 which	 remained	 significant	 after	342 
adjusting	 for	 multiple	 testing.	 Figure	 2	 shows	 relaxation	 of	 the	 assumption	 that	 the	343 
correlation	 between	 the	 errors	 in	 Xk	 and	 Yk	 is	 zero	 for	 each	 of	 the	 atopy-related	 traits	344 
demonstrating	the	consistency	of	findings.	Specifically,	for	a	correlation	in	the	range	-0.15	to	345 
0.15	the	association	between	atopic	dermatitis	and	glioma	risk	remained	significant.	346 
	347 
In	contrast	to	findings	from	IVW	and	MLE,		no	significant	support	was	provided	by	either	the	348 
WME	or	MBE	 for	 an	 association	 between	 any	 of	 the	 atopy-related	 traits	 and	 glioma	 risk,	349 
including	atopic	dermatitis	(WME:	OR=0.96,	95%	CI=0.91-1.01,	P=0.114;	MBE:	OR=0.97,	95%	350 
CI:	0.92-1.02,	P=0.194;	Table	2).	351 
	352 
The	respective	effect	estimated	from	MR-Egger	regression	(Figure	3)	 for	atopic	dermatitis,	353 
IgE,	 asthma	and	hay	 fever,	 and	 self-reported	allergy	were	0.97	 for	 atopic	dermatitis	 (95%	354 
CI=0.92-1.03;	P=0.375)	0.63	for	IgE	levels	(95%	CI=0.32-1.25;	P=0.184),	0.99	for	asthma	and	355 
hay	fever	(95%	CI=0.72-1.36,	P=0.951)	and	0.92	for	self-reported	allergy	(95%	CI=0.69-1.22;	356 
P=0.540),	with	 intercepts	of	 -0.004	 (95%	CI=-0.014-0.006,	P=0.396),	0.027	 (95%	CI=-0.001-357 
0.053,	 P=0.042),	 -0.007	 (95%	 CI=-0.030-0.016,	 P=0.542)	 and	 0.017	 (95%	 CI=0.003-0.031,	358 
P=0.018).	Collectively	these	findings	provide	possible	evidence	of	systematic	bias	in	the	IVW	359 
estimate	 for	 IgE	 level	 and	 self-reported	 allergy,	 which	might	 have	 arisen	 through	 overall	360 
unbalanced	horizontal	pleiotropy.	There	was	no	such	evidence	for	such	pleiotropy	in	respect	361 
of	atopic	dermatitis.		362 
	363 
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We	explored	the	possibility	that	a	relationship	between	atopy	and	glioma	might	be	subtype	364 
specific,	 considering	 GBM	 and	 non-GBM	 separately.	 Imposing	 a	 stronger	 significance	365 
threshold	 of	P=0.00625	 (0.05/8,	 to	 correct	 for	 testing	 four	 traits	 over	 two	 outcomes),	 no	366 
histology-specific	 associations	were	 shown	 by	 the	 IVW	method	 between	 asthma	 and	 hay	367 
fever,	 IgE	 levels	 and	 self-reported	 allergy	 and	 glioma	 risk,	 respective	 ORs	 for	 the	 IVW	368 
method	 being	 0.97,	 0.92,	 and	 1.04	 for	 GBM	 tumours,	 0.96,	 0.97,	 and	 1.04	 for	 non-GBM	369 
tumours	 (Additional	 file	 7:	 Table	 S6).	 For	 atopic	dermatitis,	 a	 significant	OR	of	 0.94	 (95%	370 
CI=0.90-0.98,	P=0.004)	was	shown	for	GBM	but	not	 for	non-GBM	(OR=0.98,	95%	CI=	0.93-371 
1.03,	 P=0.421).	 The	 association	 between	 atopic	 dermatitis	 and	 risk	 of	 GBM	 was	 also	372 
apparent	in	the	MLE	analysis,	which	provided	an	OR	of	0.94	(95%	CI=0.91-0.97,	P=2.17	x	10-373 
4).	MR-Egger	regression	provided	for	an	intercept	of	-0.007	(95%	CI=-0.019-0.005,	P=0.247).	374 
As	with	the	analysis	of	all	glioma	the	association	between	atopic	dermatitis	and	GBM	was	375 
weaker	under	the	WME	(OR=0.96,	95%	CI=0.91-1.02,	P=0.172)	and	MBE	(OR=0.95,	95%	CI=	376 
0.90-1.01,	P=0.096)	frameworks.	377 
	378 
Although	previously	 implemented	 in	other	 studies	 [32,	38],	 ratio	estimators	may	not	 fully	379 
recapitulate	 an	 estimate	 of	 the	 causal	 OR	 in	 the	 case	 of	 binary-exposures	 such	 as	 atopic	380 
dermatitis,	 and	 binary-outcomes	 such	 as	 glioma	 [39].	 We	 therefore	 evaluated	 through	381 
simulation	 whether	 the	 IVW,	 MLE,	 WME,	 MBE	 and	 MR-Egger	 methods	 provide	 reliable	382 
estimates	of	causal	ORs.	When	no	causal	relationship	between	exposure	and	outcome	was	383 
simulated,	each	MR	method	provided	accurate	estimates	of	the	null	relationship	(Additional	384 
file	6:	Table	S5).	Conversely	when	a	causal	relationship	was	simulated	the	magnitudes	of	the	385 
relationship	estimates	were	weakly	inflated	in	some	instances	(Additional	file	6:	Table	S5),	386 
indicating	 the	 importance	 of	 considering	 additional	 evidence	 when	 evaluating	 causal	387 
relationships	between	binary	exposures	and	binary	outcomes.		388 
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DISCUSSION	389 
	390 
To	our	knowledge,	this	is	the	first	MR	study	evaluating	a	range	of	atopy	related	traits	with	391 
glioma	risk	undertaken.	Overall	our	results	provide	evidence	for	a	causal	protective	effect	of	392 
atopic	 dermatitis	 with	 GBM	 tumours,	 but	 do	 not	 provide	 evidence	 that	 asthma	 and	 hay	393 
fever,	 raised	 IgE	 levels,	or	 self-reported	allergy	 is	protective	against	 the	 risk	of	developing	394 
glioma.		395 
	396 
Possible	 mechanisms	 explaining	 an	 observed	 inverse	 relation	 between	 the	 risk	 of	 atopic	397 
dermatitis	and	the	risk	of	glioma	have	been	suggested	in	previous	papers	[12],	postulated	to	398 
be	the	consequence	of	the	hyperactivity	of	the	immune	system.	The	question	thus	arises	as	399 
to	how	such	divergent	findings	for	other	atopic	traits	can	be	explained	or	reconciled,	when	400 
they	have	been	previously	reported	in	high	numbers.	401 
	402 
A	key	assumption	 in	MR	 is	 that	 the	 instrument	 affects	 glioma	 risk	 through	 its	 effect	on	a	403 
specific	phenotype/exposure	(i.e.	atopic	traits),	and	does	not	have	a	direct	effect	on	glioma	404 
risk.	We	 tested	 this	 assumption	using	MR-Egger	 regression	 and	HEIDI	 outlier	 analysis	 and	405 
found	possible	evidence	of	violation	of	this	assumption	for	IgE	and	self-reported	allergy.	It	is	406 
notable	 that	 self-reported	 allergy	 does	 not	 show	 an	 approximately	 quadratic	 response	 to	407 
correlation,	 in	 contrast	 to	 asthma	 and	 hay	 fever,	 atopic	 dermatitis,	 and	 IgE	 level.	 This	 is	408 
likely	 to	 be	 a	 consequence	 of	 imprecise	 estimates	 of	 the	 association	 between	 SNPs	 and	409 
allergy,	illustrating	the	inherent	issue	in	attempting	to	make	use	of	self-reported	allergy	data	410 
as	an	atopy-related	trait.	411 
	412 
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The	meta-analyses	of	published	epidemiological	observational	studies	have	indeed	provided	413 
strong	evidence	 for	an	 inverse	 relationship	between	atopy	and	glioma	risk	 [40].	However,	414 
most	 of	 the	 support	 for	 such	 a	 relationship	 comes	 from	 the	 case-control	 studies	 [4].	 A	415 
common	limitation	in	retrospective	studies	of	glioma	has	been	the	use	of	proxy	respondents	416 
for	 cases	 who	 have	 cognitive	 impairment.	 A	 related	 issue	 is	 that	 glioma	 cases	 may	 not	417 
remember	 past	 exposures	 accurately	 due	 to	 cognitive	 deficits	 [4].	 Such	 issues	 are	418 
compounded	by	the	fact	that	across	studies	multiple	atopic	traits	have	been	assessed.	The	419 
strength	of	 support	 for	a	 relationship	 seen	across	 case-control	 studies	 contrasts	markedly	420 
with	the	limited	the	evidence	for	a	relationship	from	prospective	cohort-based	analyses	[7].			421 
	422 
By	 inference,	 a	 relationship	 between	 long-term	 antihistamine	 use	 could	 theoretically	423 
provide	 supporting	 evidence,	 albeit	 indirect,	 that	 atopic	 mediated	 mechanisms	 influence	424 
glioma	risk.	However,	the	impact	of	antihistamine	use	is	difficult	to	disentangle	from	that	of	425 
allergies,	 as	 these	 factors	 are	 highly	 correlated,	 and	 few	 individuals	without	 allergies	 use	426 
antihistamines	 regularly.	 Paradoxically	 an	 increased	 risk	 for	 glioma	 associated	 with	427 
antihistamine,	 particularly	 among	 individuals	 with	 allergic	 conditions,	 has	 been	 found	 in	428 
some	studies	[41,	42].		429 
	430 
Raised	 IgE	 levels	 and	 self-reported	 allergy	 suffer	 limitations	 as	 traits	 used	 to	 assess	 the	431 
effect	of	atopy	on	glioma	risk	as	they	are	both	variable	over	short	time	scales	in	their	level	432 
of	expression	 (in	 contrast	 to	 clinical	diagnosis	of	 atopic	dermatitis).	 Further,	 allergies	may	433 
develop	later	in	life,	and	patients	may	not	necessarily	exhibit	symptoms.	This	introduces	the	434 
possibility	 of	 bias	 and	 error	 due	 to	 time	 varying	 association	 of	 SNPs	 with	 the	 exposure.	435 
However,	it	has	been	suggested	that	seasonality	does	not	have	a	significant	effect	[11].	Th	436 
	437 
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An	additional	possible	explanation	for	the	lack	of	causal	association	between	IgE	levels	and	438 
glioma	risk	seen	 in	this	study	 is	 that	the	causality	 is	 in	 fact	reversed,	which	could	result	 in	439 
epidemiological	observational	 studies	 reporting	 inverse	 relationships	 [8,	9],	but	would	not	440 
affect	an	MR	analysis.	Immunosuppression	caused	by	glioblastoma	is	well	documented	[43,	441 
44]	 and	 may	 lead	 to	 reduced	 expression	 of	 atopy.	 Furthermore,	 in	 addition	 to	 steroids,	442 
temozolomide	therapy,	routinely	used	to	treat	GBM	nowadays,	leads	to	reduced	blood	IgE	443 
levels	[11].		444 
	445 
Using	data	from	large	genetic	consortia	for	multiple	atopy-related	traits	and	glioma	risk	has	446 
enabled	us	to	more	precisely	test	our	study	hypotheses	than	if	we	had	used	individual-level	447 
data	from	a	smaller	study.	Through	simulation	scenarios,	the	IVW,	MLE,	WME,	MBE	and	MR-448 
Egger	 methods	 have	 been	 demonstrated	 to	 accurately	 estimate	 causal	 effects	 using	449 
summary-level	 data	 [28,	 30,	 31,	 45].	 However,	 using	 summary-level	 data	 instead	 of	450 
individual-level	data	 limits	 the	approaches	 that	 can	be	used	 to	 test	 the	validity	of	genetic	451 
variants	 as	 IVs,	 as	 adjusting	 for	 measured	 covariates	 and	 assessing	 gene-environment	452 
interactions	 is	 generally	 not	 possible	 using	 summary-level	 data	 [46].	 The	 first-stage	 F	453 
statistic	was	large	(>25	for	all	traits),	and	so	weak	instrument	bias	is	unlikely.	454 
	455 
Epidemiological	 observational	 studies	have	 reported	 inverse	 relationships	between	atopy-456 
related	traits	and	glioma	risk,	with	ORs	in	the	range	0.43-0.96	for	asthma	[6,	47],	0.42-0.90	457 
for	atopic	dermatitis	 [6,	47],	0.37-0.73	 for	 IgE	 levels	 [8-10]	and	0.47-0.69	 for	self-reported	458 
allergies	[4,	5,	8].	Odds	ratios	for	binary	exposures	estimated	in	this	MR	study	represent	the	459 
OR	 for	 the	 outcome	 disease	 per	 doubling	 in	 odds	 of	 the	 exposure	 disease,	 and	 the	460 
magnitudes	of	these	causal	effect	estimates	are	therefore	not	directly	comparable	to	those	461 
reported	in	observational	studies.	462 
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	463 
Our	MR	analysis	has	several	strengths.	Firstly,	by	utilising	the	random	allocation	of	genetic	464 
variants,	we	were	able	to	overcome	potential	confounding	and	reverse	causation	that	may	465 
bias	estimates	from	observational	studies,	Secondly,	given	that	a	poor	outcome	from	glioma	466 
is	almost	universal,	it	is	unlikely	that	survival	bias	will	have	influenced	study	findings.	Lastly,	467 
the	findings	from	this	study	represent	the	association	of	a	lifelong	atopy	with	glioma	in	the	468 
general	European	population.	469 
	470 
Our	 study	 does	 however	 have	 limitations.	 Firstly,	 while	 it	 is	 entirely	 appropriate	 to	471 
implement	different	MR	methods	 to	assess	 the	 robustness	of	 finding,	 they	have	different	472 
differing	power	 to	demonstrate	associations,	with	 the	WME,	MBE	and	MR-Egger	methods	473 
having	 less	power	 than	 IVW	and	MLE.	 Irrespective	of	 such	 factors	our	study	had	only	had	474 
80%	 power	 to	 detect	 ORs	 of	 1.16,	 1.09,	 1.16	 and	 1.22	 for	 asthma	 and	 hay	 fever,	 atopic	475 
dermatitis,	IgE	level	and	self-reported	allergy	respectively	(Additional	file	5:	Table	S4).	This	476 
is	a	result	of	 the	very	 low	proportion	of	variability	 in	the	atopy-related	traits	explained	by	477 
the	SNPs	used.	Hence,	we	cannot	exclude	the	possibility	that	these	traits	 influence	glioma	478 
risk,	albeit	modestly.	To	explore	this	possibility	will	require	additional	IVs	and	larger	sample	479 
sizes	affording	increased	power.	Furthermore,	it	is	possible	that	an	effect	of	atopy	on	glioma	480 
risk	 might	 be	 mediated	 through	 mechanisms	 associated	 with	 a	 trait	 that	 we	 have	 not	481 
captured	by	using	MR	to	assess	asthma	and	hay	fever,	and	self-reported	allergy.	Secondly,	a	482 
weakness	of	the	two-sample	MR	strategy	is	that	it	does	not	allow	examination	of	non-linear	483 
relationships	 between	 exposures	 and	 outcomes.	 Finally,	 we	 have	 sought	 to	 examine	484 
whether	bias	could	be	introduced	when	considering	a	binary	exposure	for	a	binary	outcome.	485 
Although	in	our	simulation	study	we	found	no	evidence	of	bias	when	estimating	non-causal	486 
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relationships,	 we	 did	 not	 extend	 our	 analysis	 to	 consider	 the	 potential	 impact	 of	 invalid	487 
SNPs.	488 
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CONCLUSIONS	512 
	513 
In	conclusion,	our	investigation	does	not	provide	strong	evidence	for	a	relationship	between	514 
atopy-related	diseases	and	risk	of	developing	glioma,	but	 findings	do	not	preclude	a	small	515 
effect	for	atopic	dermatitis.	Our	analysis	also	serves	to	illustrate	the	value	of	using	several	516 
MR	methods	to	derive	robust	conclusions.	517 
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	612 
Table	1:	Variant	and	effect	allele	with	frequencies	and	magnitude	of	effect	on	each	atopy-613 
related	trait	and	strength	of	association	with	glioma	614 
	615 
Region	 SNP	 Position	(bp)*	 Alleles**	 MAF	 Hay	Fever	and	Asthma	 Glioma	
OR	(95%	CI)	 OR	(95%	CI)	
2q12.1	 rs10197862	 102966549	 G/A	 G=0.161	 1.24	(1.16-1.32)	 0.98	(0.93−1.03)	
4p14	 rs4833095	 38799710	 C/T	 T=0.425	 1.20	(1.14-1.26)	 1.03	(0.99−1.08)	
5q22.1	 rs1837253	 110401872	 T/C	 T=0.382	 1.17	(1.11-1.23)	 0.96	(0.93−1.00)	
8q21.13	 rs7009110	 81291879	 C/T	 C=0.467	 1.14	(1.09-1.19)	 0.98	(0.94−1.01)	
9p24.1	 rs72699186	 6175855	 A/T	 T=0.110	 1.26	(1.17-1.36)	 0.97	(0.93−1.02)	
11q13.5	 rs2155219	 76299194	 G/T	 G=0.468	 1.17	(1.13-1.21)	 1.01	(0.97−1.05)	
15q22.33	 rs17294280	 67468285	 A/G	 G=0.120	 1.18	(1.12-1.25)	 0.98	(0.94−1.03)	
16p13.13	 rs62026376	 11228712	 T/C	 T=0.144	 1.17	(1.11-1.23)	 0.97	(0.93−1.01)	
17q21.1	 rs7212938	 38122680	 T/G	 G=0.473	 1.16	(1.11-1.22)	 1.00	(0.97−1.04)	
	616 
Region	 SNP	 Position*	 Alleles**	 MAF	 Atopic	Dermatitis	 Glioma	
OR	(95%	CI)	 OR	(95%	CI)	
1q21.3	 rs11205006	 152440176	 T/A	 A=0.265	 1.62	(1.48-1.77)	 0.96	(0.91−1.02)	
1q21.3	 rs2228145	 154426970	 A/C	 C=0.293	 1.15	(1.10-1.20)	 0.99	(0.96−1.03)	
2p25.1	 rs10199605	 8495097	 A/G	 A=0.244	 1.04	(1.03-1.06)	 1.01	(0.97−1.05)	
2p13.3	 rs112111458	 71100105	 G/A	 G=0.224	 1.08	(1.05-1.10)	 0.98	(0.92−1.03)	
2q24.3	 rs6720763	 167992286	 T/C	 C=0.320	 1.29	(1.18-1.41)	 1.02	(0.97−1.06)	
5p13.2	 rs10214237	 35883734	 C/T	 C=0.176	 1.06	(1.05-1.08)	 0.98	(0.94−1.02)	
5q31.1	 rs1295686	 131995843	 C/T	 T=0.422	 1.35	(1.22-1.49)	 0.99	(0.95−1.03)	
6p21.32	 rs12153855	 32074804	 T/C	 C=0.125	 1.58	(1.40-1.78)	 0.97	(0.92−1.03)	
8q21.13	 rs6473227	 81285892	 A/C	 A=0.473	 1.06	(1.05-1.08)	 0.98	(0.94−1.02)	
9p21.3	 rs10738626	 22373457	 C/T	 C=0.397	 1.23	(1.15-1.32)	 0.96	(0.93−1.00)	
10p15.1	 rs6602364	 6038853	 G/C	 G=0.492	 1.05	(1.03-1.07)	 1.03	(0.99−1.07)	
11q13.1	 rs10791824	 65559266	 A/G	 G=0.490	 1.15	(1.12-1.19)	 0.99	(0.95−1.02)	
11q24.3	 rs7127307	 128187383	 C/T	 C=0.488	 1.09	(1.07-1.11)	 0.99	(0.95−1.03)	
11q13.5	 rs7130588	 76270683	 G/A	 G=0.216	 1.29	(1.20-1.38)	 1.02	(0.98−1.06)	
14q13.2	 rs2143950	 35572357	 C/T	 T=0.215	 1.08	(1.06-1.10)	 1.01	(0.97−1.06)	
16p13.13	 rs2041733	 11229589	 C/T	 T=0.496	 1.09	(1.06-1.11)	 0.97	(0.94−1.01)	
19p13.2	 rs2164983	 8789381	 C/A	 A=0.169	 1.16	(1.10-1.22)	 0.95	(0.90−1.00)	
20q13.33	 rs909341	 62328742	 T/C	 T=0.262	 1.32	(1.21-1.44)	 1.32	(1.26−1.37)	
	617 
Region	 SNP	 Position*	 Alleles**	 MAF	 IgE	level***	 Glioma	
OR	(95%	CI)	 OR	(95%	CI)	
1q23.2	 rs2251746	 159272060	 C/T	 C=0.015	 1.09	(1.08-1.11)	 0.98	(0.95−1.02)	
5q31.1	 rs20541	 131995964	 A/G	 A=0.270	 1.08	(1.06-1.10)	 1.01	(0.97−1.06)	
6p22.1	 rs2571391	 29923838	 C/A	 C=0.303	 1.06	(1.05-1.08)	 0.97	(0.94−1.01)	
6p21.32	 rs2858331	 32681277	 A/G	 G=0.490	 1.04	(1.03-1.06)	 1.02	(0.98−1.06)	
12q13.3	 rs1059513	 57489709	 C/T	 C=0.070	 1.13	(1.09-1.17)	 0.97	(0.92−1.03)	
	618 
Region	 SNP	 Position*	 Alleles**	 MAF	 Self-reported	allergy	 Glioma	
OR	(95%	CI)	 OR	(95%	CI)	
2q12.1	 rs10189699	 102879464	 A/C	 A=0.143	 1.16	(1.12-1.20)	 0.99	(0.94−1.04)	
2q33.1	 rs10497813	 198914072	 T/G	 T=0.401	 1.08	(1.05-1.11)	 0.99	(0.96−1.03)	
3q28	 rs9860547	 188128979	 G/A	 A=0.272	 1.08	(1.05-1.11)	 1.02	(0.98−1.06)	
4p14	 rs2101521	 38811551	 A/G	 A=0.475	 1.15	(1.12-1.18)	 1.02	(0.98−1.07)	
4q27	 rs17388568	 123329369	 G/A	 A=0.141	 1.08	(1.05-1.11)	 1.01	(0.97−1.05)	
5p13.1	 rs7720838	 40486896	 G/T	 T=0.362	 1.08	(1.06-1.11)	 1.02	(0.99−1.06)	
5q22.1	 rs1438673	 110467499	 T/C	 C=0.296	 1.12	(1.09-1.15)	 0.97	(0.94−1.01)	
6p21.33	 rs9266772	 31352113	 T/C	 C=0.175	 1.11	(1.08-1.14)	 1.03	(0.98−1.08)	
9p24.1	 rs7032572	 6172380	 A/G	 G=0.114	 1.12	(1.08-1.16)	 0.97	(0.93−1.02)	
10p14	 rs962993	 9053132	 T/C	 T=0.106	 1.07	(1.05-1.10)	 1.02	(0.98−1.06)	
11q13.5	 rs2155219	 76999194	 G/T	 G=0.468	 1.11	(1.09-1.14)	 1.01	(0.97−1.05)	
15q22.33	 rs17228058	 67450305	 A/G	 G=0.100	 1.08	(1.05-1.11)	 1.00	(0.96−1.04)	
17q21.1	 rs9303280	 38074031	 T/C	 T=0.346	 1.07	(1.05-1.09)	 0.98	(0.94−1.02)	
20q13.2	 rs6021270	 50141264	 C/T	 T=0.346	 1.16	(1.10-1.22)	 1.02	(0.94−1.10)	
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*	NCBI	build	37;	**	Reference	allele/effect	allele;	***	per	standard	deviation;	MAF=	minor	619 
allele	frequency;	OR=	odds	ratio	620 
Table	 2:	 IVW,	 MLE,	 WME,	 MBE	 and	 MR-Egger	 test	 results	 for	 combined	 atopy-related	621 
instrumental	variables	622 
	623 
Trait	 IVW	 MLE	 WME	 MBE	 MR-Egger	slope	 MR-Egger	intercept	
OR	(95%	CI)	 P	 OR	(95%	CI)	 P	
OR	(95%	CI)	 P	
OR	(95%	CI)	 P	 OR	(95%	CI)	 P	 Estimate	(95%	CI)	 P	
Asthma	
and	hay	
fever	
0.96	(0.90-1.03)	 0.248	 0.96	(0.93-1.00)	 0.066	 0.93	(0.86-1.01)	 0.087	 0.91	(0.80-1.04)	 0.191	 0.99	(0.72-1.36)	 0.951	 -0.007	(-0.030-0.016)	 0.542	
Atopic	
dermatitis	
0.96	(0.93-1.00)	 0.041	 0.96	(0.94-0.99)	 0.003	 0.96	(0.91-1.01)	 0.114	 0.97	(0.92-1.02)	 0.194	 0.97	(0.92-1.03)	 0.375	 0.004	(-0.014-0.006)	 0.396	
IgE	level	 0.88	(0.69-1.13)	 0.319	 0.88	(0.74-1.05)	 0.157	 0.83	(0.61-1.12)	 0.218	 0.82	(0.57-1.19)	 0.355	 0.63	(0.32-1.25)	 0.184	 0.027	(0.001-0.053)	 0.042	
Self-
reported	
allergy	
1.03	(0.95-1.11)	 0.534	 1.02	(0.97-1.08)	 0.429	 1.08	(0.97-1.20)	 0.184	 1.12	(0.92-1.36)	 0.275	 0.92	(0.69-1.22)	 0.540	 0.017	(0.003-0.031)	 0.018	
	624 
IVW=	 inverse	 variance	 weighted;	MLE=	maximum	 likelihood	 estimation;	WME=	weighted	625 
median	estimate;	MBE=	mode-based	estimate	626 
	627 
	628 
	629 
	630 
	631 
	632 
	633 
	634 
	635 
	636 
	637 
	638 
	639 
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Figure	 1:	 Forest	 plot	 of	 Wald	 ORs	 and	 95%	 confidence	 intervals	 generated	 from	 SNPs	640 
associated	 with	 atopy-related	 traits.	 ORs	 for	 individual	 SNPs	 are	 listed	 according	 to	641 
magnitude	 of	 effect	 in	 the	 instrumental	 variable	 analysis	 and	 are	 presented	with	 pooled	642 
effects	using	the	IVW	method.	Squares	represent	the	point	estimate,	and	the	bars	are	the	643 
95%	confidence	intervals.	 	(a)	Asthma	and	hay	fever,	(b)	atopic	dermatitis,	(c)	IgE	level,	(d)	644 
self-reported	allergy.	645 
	646 
	647 
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Figure	 2:	 Plot	 of	 P	 value	 of	 MLE	 associations	 with	 glioma	 against	 correlation	 between	648 
errors	 in	Xk	 and	Yk.	 (a)	Asthma	and	hay	 fever,	 (b)	 atopic	dermatitis,	 (c)	 IgE	 level,	 (d)	 self-649 
reported	allergy.		650 
	651 
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Figure	 3:	 Scatter	 plots	 of	 genetic	 associations	 with	 glioma	 against	 genetic	 associations	652 
with	 the	 exposure.	 (a)	 Asthma	 and	 hay	 fever,	 (b)	 atopic	 dermatitis,	 (c)	 IgE	 level,	 (d)	 self-653 
reported	allergy.			654 
	655 
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ADDITIONAL	FILES	656 
	657 
Additional	file	1:	Figure	S1:	Forest	plot	of	Wald	ORs	and	95%	confidence	intervals	generated	658 
from	SNPs	associated	with	atopic	dermatitis,	including	rs909341.	ORs	for	individual	SNPs	are	659 
listed	 according	 to	 magnitude	 of	 effect	 in	 the	 instrumental	 variable	 analysis	 and	 are	660 
presented	with	pooled	effects	using	the	IVW	method.	Squares	represent	the	point	estimate,	661 
and	the	bars	are	the	95%	confidence	intervals.	(DOCX	92	kb)	662 
	663 
Additional	file	2:	Table	S1:	Summary	of	the	eight	glioma	genome-wide	association	studies.	664 
(XLSX	30	kb)	665 
	666 
Additional	file	3:	Table	S2:	Table	of	SNPs	reported	in	the	NHGRI-EBI	GWAS	Catalog	for	each	667 
trait,	with	correlations	between	SNPs.	(XLSX	50	kb)	668 
	669 
Additional	file	4:	Table	S3:	Percentage	of	variance	explained	by	the	combined	sets	of	SNPs	670 
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Additional	file	5:	Table	S4:	Range	of	ORs	for	which	study	had	<80%	power,	for	each	atopy-673 
related	trait	(P=0.05,	two-sided).	(XLSX	9	kb)	674 
	675 
Additional	file	6:	Table	S5:	Simulation	analyses.	(XLSX	30	kb)	676 
	677 
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Figure	S1:	Forest	plot	of	Wald	ORs	and	95%	confidence	intervals	generated	from	SNPs	associated	with	atopic	dermatitis,	including	rs909341.	ORs	for	individual	SNPs	
are	listed	according	to	magnitude	of	effect	in	the	instrumental	variable	analysis	and	are	presented	with	pooled	effects	using	the	IVW	method.	Squares	represent	the	
point	estimate,	and	the	bars	are	the	95%	confidence	intervals.	
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Table	S1:	Summary	of	the	eight	glioma	genome-wide	association	studies
Series Study	centre
FRE Groupe	Hospitalier	Pitié-Salpêtrière	Paris
GER University	of	Bonn
GICC GLIOGENE	Consortium
MDA The	University	of	Texas	M.D.	Anderson	
Cancer	Center
GiomaScan	
(NIH)
National	Cancer	Institute	
UCSF-Mayo Mayo	Clinic
UCSF	
(SFAGS)
University	of	California,	San	Francisco
UK INTERPHONE
Total
Table	S1:	Summary	of	the	eight	glioma	genome-wide	association	studies
Sampling
Patients	with	glioma	were	ascertained	through	the	Service	de	Neurologie	Mazarin,	Groupe	
Hospitalier	Pitié-Salpêtrière	Paris.	Controls	were	ascertained	from	the	SU.VI.MAX	
(Supplementation	en	Vitamines	et	MinerauxAntioXydants)	study.	
Comprised	of	patients	who	had	undergone	surgery	for	a	glioma	at	the	Department	of	
Neurosurgery,	University	of	Bonn	Medical	Center,	between	1996	and	2008.	Control	subjects	
were	taken	from	three	population	studies:	KORA	(Co-	operative	Health	Research	in	the	Region	
of	Augsburg);	POPGEN	(Population	Genetic	Cohort)	and	the	Heinz	Nixdorf	Recall	study.
Comprise	glioma	cases	and	controls	that	were	ascertained	through	Brigham	and	Women's	
Hospital	(Boston,	Massachusetts),	Case	Western	Reserve	University	(Cleveland,	Ohio),	Columbia	
University	(New	York,	New	York),	the	Danish	Cancer	Society	Research	Centre	(Copenhagen,	
Denmark),	the	Gertner	Institute	(Tel	Hashomer,	Israel),	Duke	University	(Durham,	North	
Carolina),	the	University	of	Texas	MD	Anderson	Cancer	Center	(Houston,	Texas),	Memorial	
Sloan	Kettering	Cancer	Center	(New	York,	New	York),	the	Mayo	Clinic	(Rochester,	Minnesota),	
NorthShore	HealthSystem	(Chicago,	Illinois),	Umeå	University	(Umeå,	Sweden),	the	University	
of	California,	San	Francisco	(San	Francisco,	California),	the	University	of	Southern	California	(Los	
Angeles,	California),	and	the	Institute	of	Cancer	Research	(London,	United	Kingdom).	Cases	had	
newly	diagnosed	glioma,	and	controls	had	no	personal	history	of	central	nervous	system	tumor	
at	the	time	of	ascertainment
Cases	were	ascertained	through	the	MD	Anderson	Cancer	Center,	Texas,	between	1990	and	
2008.	Individuals	from	the	Cancer	Genetic	Markers	of	Susceptibility	studies	served	as	controls.
Cases	were	newly	diagnosed	glioma	[ICDO-3	codes	9380-9480	or	equivalent],	and	controls	were	
cancer-free	at	the	time	of	glioma	diagnosis.
Comprised	of	Mayo	cases,	UCSF	cases,	and	Mayo	Clinic	Biobank	control	data
Cases	were	adults	with	newly	diagnosed,	histologically	confirmed	glioma.	Population-based	
cases	who	were	diagnosed	between	1991	and	2009	and	who	were	residing	in	the	six	San	
Francisco	Bay	area	counties	were	ascertained	using	the	Cancer	Prevention	Institute	of	
California's	early-case	ascertainment	system.	Clinic-based	cases	who	were	diagnosed	between	
2002	and	2012	were	recruited	from	the	UCSF	Neuro-oncology	Clinic,	regardless	of	the	place	of	
residence.	From	1991	to	2010,	population-based	controls	from	the	same	residential	area	as	the	
population-based	cases	were	identified	using	random	digit-dialing	and	were	frequency	matched	
to	population-based	cases	for	age,	gender	and	ethnicity.	Between	2010	and	2012,	all	controls	
were	selected	from	the	UCSF	general	medicine	phlebotomy	clinic.	Clinic-based	controls	were	
matched	to	clinic-based	glioma	cases	for	age,	gender	and	ethnicity.
Cases	were	ascertained	through	the	INTERPHONE	study.	Individuals	from	the	1958	Birth	Cohort	
served	as	a	source	of	controls.
No.	
cases
No.	
controls
1,423 1,190
846 1,310
4,564 3,265
1,175 2,236
1,653 2,725
1,519 804
677 3,940
631 2,699
12,488 18,169
Table	S2:	Table	of	SNPs	reported	in	the	NHGRI-EBI	GWAS	Catalog	for	each	trait,	with	correlations	between	SNPs
Asthma	and	
hay	fever Chr 2 4 5 5 8 9 11 15 16
Chr rsid rs10197862 rs4833095 rs1438673 rs1837253 rs7009110 rs72699186 rs2155219 rs17294280 rs62026376
2 rs10197862 1
4 rs4833095 0 1
5 rs1438673 0 0 1
5 rs1837253 0 0 0.0290264 1
8 rs7009110 0 0 0 0 1
9 rs72699186 0 0 0 0 0 1
11 rs2155219 0 0 0 0 0 0 1
15 rs17294280 0 0 0 0 0 0 0 1
16 rs62026376 0 0 0 0 0 0 0 0 1
17 rs7212938 0 0 0 0 0 0 0 0 0
Atopic	
Dermatitis Chr 1 1 1 1 1 1 2 2 2
Chr rsid rs11205006 rs12144049 rs2228145 rs61813875 rs6661961 rs7512552 rs10199605 rs112111458rs6419573
1 rs11205006 1
1 rs12144049 1 1
1 rs2228145 0.00033237 9.48E-05 1
1 rs61813875 0.0346025 0.0746275 2.95E-05 1
1 rs6661961 0.477915 0.5082 0.00028748 0.0345781 1
1 rs7512552 0.002187 0.00051363 1.61E-05 0.00016209 0.00036636 1
2 rs10199605 0 0 0 0 0 0 1
2 rs112111458 0 0 0 0 0 0 0.00011906 1
2 rs6419573 0 0 0 0 0 0 2.76E-05 0.0033077 1
2 rs6720763 0 0 0 0 0 0 0.00011986 6.94E-05 0.00242265
5 rs10214237 0 0 0 0 0 0 0 0 0
5 rs12188917 0 0 0 0 0 0 0 0 0
5 rs1295686 0 0 0 0 0 0 0 0 0
5 rs2897442 0 0 0 0 0 0 0 0 0
5 rs4705962 0 0 0 0 0 0 0 0 0
6 rs12153855 0 0 0 0 0 0 0 0 0
6 rs41268896 0 0 0 0 0 0 0 0 0
6 rs4713555 0 0 0 0 0 0 0 0 0
8 rs6473227 0 0 0 0 0 0 0 0 0
9 rs10738626 0 0 0 0 0 0 0 0 0
10 rs6602364 0 0 0 0 0 0 0 0 0
11 rs10791824 0 0 0 0 0 0 0 0 0
11 rs2212434 0 0 0 0 0 0 0 0 0
11 rs479844 0 0 0 0 0 0 0 0 0
11 rs7127307 0 0 0 0 0 0 0 0 0
11 rs7130588 0 0 0 0 0 0 0 0 0
11 rs7927894 0 0 0 0 0 0 0 0 0
14 rs2143950 0 0 0 0 0 0 0 0 0
16 rs2041733 0 0 0 0 0 0 0 0 0
19 rs2164983 0 0 0 0 0 0 0 0 0
19 rs2918307 0 0 0 0 0 0 0 0 0
20 rs4809219 0 0 0 0 0 0 0 0 0
20 rs6010620 0 0 0 0 0 0 0 0 0
20 rs909341 0 0 0 0 0 0 0 0 0
IgE	levels Chr 1 1 1 5 6 6 6 12
Chr rsid rs4656784 rs13962 rs2251746 rs20541 rs2858331 rs2571391 rs2523809 rs1059513
1 rs4656784 1
1 rs13962 0.3643 1
1 rs2251746 0.462008 0.410714 1
5 rs20541 0 0 0 1
6 rs2858331 0 0 0 0 1
6 rs2571391 0 0 0 0 0.00010884 1
6 rs2523809 0 0 0 0 0.0130407 0.0648709 1
12 rs1059513 0 0 0 0 0 0 0 1
Self-
reported	
allergy Chr 2 4 5 5 8 9 11 15 16
Chr rsid rs10197862 rs4833095 rs1438673 rs1837253 rs7009110 rs72699186 rs2155219 rs17294280 rs62026376
2 rs10197862 1
4 rs4833095 0 1
5 rs1438673 0 0 1
5 rs1837253 0 0 0.0290264 1
8 rs7009110 0 0 0 0 1
9 rs72699186 0 0 0 0 0 1
11 rs2155219 0 0 0 0 0 0 1
15 rs17294280 0 0 0 0 0 0 0 1
16 rs62026376 0 0 0 0 0 0 0 0 1
17 rs7212938 0 0 0 0 0 0 0 0 0
17
rs7212938
1
2 5 5 5 5 5 6 6 6 8 9
rs6720763 rs10214237 rs12188917 rs1295686 rs2897442 rs4705962 rs12153855 rs41268896 rs4713555 rs6473227 rs10738626
1
0 1
0 0.00239469 1
0 5.00E-06 0.24802 1
0 0.0002101 0.0239946 0.162452 1
0 0.00047095 0.0348378 0.180208 0.858099 1
0 0 0 0 0 0 1
0 0 0 0 0 0 0.0452232 1
0 0 0 0 0 0 0.18826 0.0275876 1
0 0 0 0 0 0 0 0 0 1
0 0 0 0 0 0 0 0 0 0 1
0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0
17
rs7212938
1
10 11 11 11 11 11 11 14 16 19 19
rs6602364 rs10791824 rs2212434 rs479844 rs7127307 rs7130588 rs7927894 rs2143950 rs2041733 rs2164983 rs2918307
1
0 1
0 0.00026763 1
0 0.938237 0.00055208 1
0 0.00037286 0.00059044 0.00025972 1
0 0.00024611 0.674246 0.00036951 0.00047794 1
0 0.00028194 0.597991 0.00067521 0.00095006 0.84696 1
0 0 0 0 0 0 0 1
0 0 0 0 0 0 0 0 1
0 0 0 0 0 0 0 0 0 1
0 0 0 0 0 0 0 0 0 1 1
0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0

20 20 20
rs4809219 rs6010620 rs909341
1
0.0985128 1
0.748019 0.756937 1
Table	S3:	Percentage	of	variance	explained	by	the	combined	sets	of	SNPs	used	as	IVs.
Trait
Number	of	SNPs	
used	as	IV
Percentage	of	
variance	explained	
Asthma	and	hay	fever 9 2.1
Atopic	dermatitis 18 6.9
IgE	levels 5 4.8
Self-reported	allergy 14 1.3
Table	S4:	Range	of	ORs	for	which	study	had	<80%	power,	for	each	atopy-related	trait	(P=0.05,	two-sided).
All	glioma GBM non-GBM
Asthma	and	hay	fever 0.86-1.16 0.82-1.22 0.82-1.22
Atopic	dermatitis 0.92-1.09 0.89-1.11 0.89-1.11
IgE	levels 0.86-1.16 0.83-1.21 0.83-1.21
Self-reported	allergy 0.82-1.22 0.78-1.29 0.77-1.29
Trait
<80%	ORs
Table	S5:	Simulation	analyses.
Exposure
Asthma	and	hay	fever i 1.00 9 6,685 14,091 12,488 18,169 0.010
Atopic	dermatitis i 1.00 18 21,399 95,464 12,488 18,169 0.092
Self-reported	allergy i 1.00 14 26,311 27,551 12,488 18,169 0.044
Asthma	and	hay	fever ii 1.33 9 6,685 14,091 12,488 18,169 0.015
Atopic	dermatitis ii 1.33 18 21,399 95,464 12,488 18,169 0.110
Self-reported	allergy ii 1.33 14 26,311 27,551 12,488 18,169 0.058
IVW:	inverse	variance	weighted;	MLE:	maximum	likelihood	estimate;	WME:	weighted	median	estimate;	MBE:	mode-based	estimate;	OR:	odds	ratio;	SD:	standard	deviation
Mean	simulated	disease	prevalence
Simulation	results
Trait
Number	of	
genetic	
variants	
used	as	IVs
Number	of	
controls	in	
outcome	
GWAS
Number	of	
cases	in	
outcome	
GWAS
Number	of	
controls	in	
exposure	
GWASScenario
Simulation	parameters
Number	of	
cases	in	
exposure	
GWAS
OR	for	outcome	
per	doubling	in	
odds	of	exposure	
(v)
Outcome IVW MLE WME MBE MR-Egger
0.010 0.999	(0.015) 0.999	(0.014) 0.998	(0.018) 0.998	(0.019) 0.999	(0.027)
0.010 1.002	(0.010) 1.002	(0.009) 1.002	(0.012) 1.001	(0.014) 1.003	(0.018)
0.010 1.000	(0.014) 1.001	(0.012) 0.999	(0.015) 0.999	(0.015) 0.996	(0.023)
0.001 1.327	(0.022) 1.329	(0.025) 1.326	(0.027) 1.327	(0.026) 1.324	(0.046)
0.004 1.359	(0.029) 1.355	(0.031) 1.356	(0.029) 1.357	(0.029) 1.356	(0.030)
0.003 1.343	(0.027) 1.338	(0.028) 1.343	(0.028) 1.343	(0.028) 1.341	(0.033)
IVW:	inverse	variance	weighted;	MLE:	maximum	likelihood	estimate;	WME:	weighted	median	estimate;	MBE:	mode-based	estimate;	OR:	odds	ratio;	SD:	standard	deviation
Mean	simulated	disease	prevalence Mean	estimated	OR	(SD)
Simulation	results
Table	S6:	IVW,	MLE,	MBE	and	MR-Egger	test	results	for	combined	atopy-related	instrumental	variables	and	glioma	subtypes
Trait OR	(95%	CI) P-value OR	(95%	CI) P-value OR	(95%	CI) P-value OR	(95%	CI) P-value OR	(95%	CI)
Asthma	and	hay	fever 0.97	(0.89-1.06) 0.515 0.98	(0.93-1.03) 0.375 0.95	(0.86-1.05) 0.349 0.92	(0.75-1.12) 0.429 1.01	(0.68-1.49)
Atopic	dermatitis 0.94	(0.90-0.98) 0.004 0.94	(0.91-0.97) 2.17E-04 0.96	(0.91-1.02) 0.172 0.95	(0.90-1.01) 0.096 0.96	(0.89-1.03)
IgE	levels 0.92	(0.67-1.25) 0.587 0.92	(0.74-1.14) 0.427 0.78	(0.54-1.13) 0.191 0.77	(0.50-1.18) 0.300 0.46	(0.20-1.06)
Self-reported	allergy 1.04	(0.94-1.15) 0.473 1.04	(0.96-1.11) 0.327 1.05	(0.92-1.20) 0.463 1.06	(0.88-1.27) 0.566 0.94	(0.66-1.33)
IVW:	inverse	variance	weighted;	MLE:	maximum	likelihood	estimate;	WME:	weighted	median	estimate,	MBE:	mode-based	estimate
IVW MLE MBE MR-Egger
GBM
WME
P-value OR	(95%	CI) P-value OR	(95%	CI) P-value OR	(95%	CI) P-value OR	(95%	CI) P-value OR	(95%	CI) P-value
0.985 0.96	(0.90-1.04) 0.325 0.96	(0.91-1.02) 0.161 0.95	(0.86-1.05) 0.343 0.92	(0.79-1.07) 0.313 0.91	(0.60-1.39) 0.656
0.237 0.98	(0.93-1.03) 0.421 0.99	(0.96-1.03) 0.602 0.96	(0.90-1.03) 0.267 0.96	(0.90-1.02) 0.236 0.96	(0.89-1.04) 0.320
0.067 0.97	(0.70-1.35) 0.853 0.97	(0.77-1.22) 0.791 1.09	(0.74-1.62) 0.651 1.11	(0.71-1.72) 0.670 1.21	(0.59-2.94) 0.668
0.718 1.04	(0.94-1.15) 0.473 1.04	(0.96-1.11) 0.327 1.05	(0.92-1.20) 0.446 1.06	(0.86-1.29) 0.601 0.77	(0.53-1.13) 0.178
MR-Egger
GBM Non-GBM	glioma
IVW MLE MBE MR-EggerWME
